FDA Expands Approval For AstraZeneca’s Drug For Pediatric Patients With Rare Type Of Cancer

All NewsSeptember 10, 2025

The FDA approved AstraZeneca’s Koselugo for children 1+ with NF1 and inoperable nerve tumors, expanding treatment options with an established safe dose.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent